The foundations of immune checkpoint blockade and the ipilimumab approval decennial von Korman, Alan J., Garrett-Thomson, Sarah C., Lonberg, Nils

Volltext

FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis von Dahan, Rony, Sega, Emanuela, Engelhardt, John, Selby, Mark, Korman, Alan J., Ravetch, Jeffrey V.

Volltext

Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology von Selby, Mark J, Engelhardt, John J, Johnston, Robert J, Lu, Li-Sheng, Han, Minhua, Thudium, Kent, Yao, Dapeng, Quigley, Michael, Valle, Jose, Wang, Changyu, Chen, Bing, Cardarelli, Pina M, Blanset, Diann, Korman, Alan J

Volltext

Evolving synergistic combinations of targeted immunotherapies to combat cancer von Melero, Ignacio, Berman, David M., Aznar, M. Angela, Korman, Alan J., Gracia, José Luis Pérez, Haanen, John

Volltext

Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy von Marciscano, Ariel E, Ghasemzadeh, Ali, Nirschl, Thomas R, Theodros, Debebe, Kochel, Christina M, Francica, Brian J, Muroyama, Yuki, Anders, Robert A, Sharabi, Andrew B, Velarde, Esteban, Mao, Wendy, Chaudhary, Kunal R, Chaimowitz, Matthew G, Wong, John, Selby, Mark J, Thudium, Kent B, Korman, Alan J, Ulmert, David, Thorek, Daniel L J, DeWeese, Theodore L, Drake, Charles G

Volltext

Blood–brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy von Galstyan, Anna, Markman, Janet L., Shatalova, Ekaterina S., Chiechi, Antonella, Korman, Alan J., Patil, Rameshwar, Klymyshyn, Dmytro, Tourtellotte, Warren G., Israel, Liron L., Braubach, Oliver, Ljubimov, Vladimir A., Mashouf, Leila A., Ramesh, Arshia, Grodzinski, Zachary B., Penichet, Manuel L., Black, Keith L., Holler, Eggehard, Sun, Tao, Ding, Hui, Ljubimov, Alexander V., Ljubimova, Julia Y.

Volltext

TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection von Chew, Glen M, Fujita, Tsuyoshi, Webb, Gabriela M, Burwitz, Benjamin J, Wu, Helen L, Reed, Jason S, Hammond, Katherine B, Clayton, Kiera L, Ishii, Naoto, Abdel-Mohsen, Mohamed, Liegler, Teri, Mitchell, Brooks I, Hecht, Frederick M, Ostrowski, Mario, Shikuma, Cecilia M, Hansen, Scott G, Maurer, Mark, Korman, Alan J, Deeks, Steven G, Sacha, Jonah B, Ndhlovu, Lishomwa C

Volltext

Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab von Ramagopal, Udupi A., Liu, Weifeng, Garrett-Thomson, Sarah C., Bonanno, Jeffrey B., Yan, Qingrong, Srinivasan, Mohan, Wong, Susan C., Bell, Alasdair, Mankikar, Shilpa, Rangan, Vangipuram S., Deshpande, Shrikant, Korman, Alan J., Almo, Steven C.

Volltext

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates von BRAHMER, Julie R, DRAKE, Charles G, GILSON, Marta M, CHANGYU WANG, SELBY, Mark, TAUBE, Janis M, ANDERS, Robert, LIEPING CHEN, KORMAN, Alan J, PARDOLL, Drew M, LOWY, Israel, TOPALIAN, Suzanne L, WOLLNER, Ira, POWDERLY, John D, PICUS, Joel, SHARFMAN, William H, STANKEVICH, Elizabeth, PONS, Alice, SALAY, Theresa M, MCMILLER, Tracee L

Volltext

A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus... von Gardiner, David, Lalezari, Jay, Lawitz, Eric, DiMicco, Michael, Ghalib, Rheem, Reddy, K Rajender, Chang, Kyong-Mi, Sulkowski, Mark, Marro, Steven O', Anderson, Jeffrey, He, Bing, Kansra, Vikram, McPhee, Fiona, Wind-Rotolo, Megan, Grasela, Dennis, Selby, Mark, Korman, Alan J, Lowy, Israel

Volltext

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma von Wolchok, Jedd D., Hodi, F. Stephen, Weber, Jeffrey S., Allison, James P., Urba, Walter J., Robert, Caroline, O'Day, Steven J., Hoos, Axel, Humphrey, Rachel, Berman, David M., Lonberg, Nils, Korman, Alan J.

Volltext

Blockade ofthe negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis von Chang, Katherine C, Burnham, Carey-Ann, Compton, Stephanie M, Rasche, David P, Mazuski, RichardJ, SMcDonough, Jacquelyn, Unsinger, Jacqueline, Korman, Alan J, Green, Jonathan M, Hotchkiss, Richard S

Volltext

Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape von Noguchi, Takuro, Ward, Jeffrey P, Gubin, Matthew M, Arthur, Cora D, Lee, Sang Hun, Hundal, Jasreet, Selby, Mark J, Graziano, Robert F, Mardis, Elaine R, Korman, Alan J, Schreiber, Robert D

Volltext

BMS-936564/MDX-1338: A Fully Human Anti-CXCR4 Antibody Induces Apoptosis In Vitro and Shows Antitumor Activity In Vivo in Hematologic Malignancies von KUHNE, Michelle R, MULVEY, Tanya, COHEN, Lewis J, KORMAN, Alan J, CARDARELLI, Pina M, BELANGER, Blake, CHEN, Sharline, PAN, Chin, COLIN CHONG, FEI CAO, NIEKRO, Wafa, KEMPE, Tom, HENNING, Karla A

Volltext

FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis von Dahan, Rony, Sega, Emanuela, Engelhardt, John, Selby, Mark, Korman, Alan J., Ravetch, Jeffrey V.

Volltext

An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients von Colston, Elizabeth, Grasela, Dennis, Gardiner, David, Bucy, R Pat, Vakkalagadda, Blisse, Korman, Alan J, Lowy, Israel

Volltext

Anticancer immunotherapy by CTLA-4 blockade： obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25 von Hannani, Dalil, Vétizou, Marie, Enot, David, Rusakiewicz, Sylvie, Chaput, Nathalie, Klatzmann, David, Desbois, Melanie, Jacquelot, Nicolas, Vimond, Nadège, Chouaib, Salem, Mateus, Christine, Allison, James P, Ribas, Antoni, Wolchok, Jedd D, Yuan, Jianda, Wong, Philip, Postow, Michael, Mackiewicz, Andrzej, Mackiewicz, Jacek, Schadendorff, Dirk, Jaeger, Dirk, Korman, Alan J, Bahjat, Keith, Maio, Michele, Calabro, Luana, Teng, Michele WL, Smyth, Mark J, Eggermont, Alexander, Robert, Caroline, Kroemer, Guido, Zitvogel, Laurence

Volltext

Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates von Brahmer, Julie R, Drake, Charles G, Wollner, Ira, Powderly, John D, Picus, Joel, Sharfman, William H, Stankevich, Elizabeth, Pons, Alice, Salay, Theresa M, McMiller, Tracee L, Gilson, Marta M, Wang, Changyu, Selby, Mark, Taube, Janis M, Anders, Robert, Chen, Lieping, Korman, Alan J, Pardoll, Drew M, Lowy, Israel, Topalian, Suzanne L

Volltext

A novel small molecule Enpp1 inhibitor improves tumor control following radiation therapy by targeting stromal Enpp1 expression von Baird, Jason R, Alice, Alejandro F, Saito, Roland, Chai, Qingqing, Han, Minhua, Ng, Cindy, Han, Stephanie, Fernandez, Beth, Ledoux, Sarah, Grosse, Johannes, Korman, Alan J, Potuznik, Megan, Rajamanickam, Venkatesh, Bernard, Brady, Crittenden, Marka R, Gough, Michael J

Volltext

Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs von Wong, Raymond M., Scotland, Ron R., Lau, Roy L., Wang, Changyu, Korman, Alan J., Kast, W. M., Weber, Jeffrey S.

Volltext